Company profile: Actinium Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical, radiotherapies, and medical research, development, and clinical trial services.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Actinium Pharmaceuticals
Vor Bio
HQ: United States
Website
- Description: Provider of immuno-oncology therapies for AML, including VOR33, a gene-edited hematopoietic stem cell therapy lacking CD33 to shield healthy blood cells from targeted therapies, and VCAR33ALLO, an allogeneic anti-CD33 CAR-T for relapsed or refractory post-transplant AML. Runs clinical trials (VBP101, VBP301) and collaborates with blood cancer advocacy groups to support the AML patient community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vor Bio company profile →
TheraPharm
HQ: Germany
Website
- Description: Provider of monoclonal antibody-based diagnostic and therapeutic biotechnology solutions in hematology, specializing in research, development, and manufacturing for targeted radiation of hematopoietic malignant and non-malignant diseases and lymphoproliferative diseases, conditioning for allogeneic stem cells, and diagnostics of inflammatory diseases and bone marrow metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TheraPharm company profile →
Oncternal Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology treatments, developing a pipeline including ONCT-808, a ROR1-targeting autologous CAR T in Phase 1/2 for relapsed or refractory aggressive B-cell lymphoma; ONCT-534, a dual-action androgen receptor inhibitor for metastatic castration-resistant prostate cancer; and zilovertamab, a ROR1-targeting monoclonal antibody evaluated with other treatments for various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncternal Therapeutics company profile →
RefleXion
HQ: United States
Website
- Description: Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RefleXion company profile →
CellGate
HQ: United States
Website
- Description: Provider of anti-proliferative pharmaceutical products and cancer therapeutics, with applications in age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellGate company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Actinium Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Actinium Pharmaceuticals
2.2 - Growth funds investing in similar companies to Actinium Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Actinium Pharmaceuticals
4.2 - Public trading comparable groups for Actinium Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →